Alnylam appears to win approval for ATTR-CM, setting up competition with Pfizer and BridgeBio
Alnylam’s drug Amvuttra appears to have been approved for a rare heart disease, giving the company an expected yet significant win. Amvuttra is now approved to treat patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, according ...
Alnylam’s drug Amvuttra appears to have been approved for a rare heart disease, giving the company an expected yet significant win.
Amvuttra is now approved to treat patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, according ...
